PL2510946T3 - Koniugaty syntetycznych agonistów tlr i ich zastosowania - Google Patents
Koniugaty syntetycznych agonistów tlr i ich zastosowaniaInfo
- Publication number
- PL2510946T3 PL2510946T3 PL12004181T PL12004181T PL2510946T3 PL 2510946 T3 PL2510946 T3 PL 2510946T3 PL 12004181 T PL12004181 T PL 12004181T PL 12004181 T PL12004181 T PL 12004181T PL 2510946 T3 PL2510946 T3 PL 2510946T3
- Authority
- PL
- Poland
- Prior art keywords
- conjugates
- tlr agonists
- uses therefor
- synthetic tlr
- synthetic
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/07—Bacillus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/085—Staphylococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
- A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
- C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
- Molecular Biology (AREA)
- Dispersion Chemistry (AREA)
- Biochemistry (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Biotechnology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US88869907P | 2007-02-07 | 2007-02-07 | |
| EP12004181.9A EP2510946B1 (en) | 2007-02-07 | 2008-02-07 | Conjugates of synthetic tlr agonists and uses therefor |
| EP08799591.6A EP2125007B9 (en) | 2007-02-07 | 2008-02-07 | Conjugates of synthetic tlr agonists and uses therefor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2510946T3 true PL2510946T3 (pl) | 2015-12-31 |
Family
ID=39766655
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL12004181T PL2510946T3 (pl) | 2007-02-07 | 2008-02-07 | Koniugaty syntetycznych agonistów tlr i ich zastosowania |
| PL08799591T PL2125007T3 (pl) | 2007-02-07 | 2008-02-07 | Koniugaty syntetycznych agonistów TLR i ich zastosowania |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL08799591T PL2125007T3 (pl) | 2007-02-07 | 2008-02-07 | Koniugaty syntetycznych agonistów TLR i ich zastosowania |
Country Status (17)
| Country | Link |
|---|---|
| US (3) | US8357374B2 (enExample) |
| EP (2) | EP2510946B1 (enExample) |
| JP (2) | JP5425642B2 (enExample) |
| KR (1) | KR20090109121A (enExample) |
| CN (1) | CN101790380B (enExample) |
| AU (1) | AU2008227128B2 (enExample) |
| CA (1) | CA2677733A1 (enExample) |
| DK (1) | DK2510946T3 (enExample) |
| EA (1) | EA019151B1 (enExample) |
| ES (2) | ES2456964T3 (enExample) |
| HU (1) | HUE025555T2 (enExample) |
| IL (1) | IL200240A (enExample) |
| PL (2) | PL2510946T3 (enExample) |
| PT (1) | PT2510946E (enExample) |
| SI (1) | SI2510946T1 (enExample) |
| WO (1) | WO2008115319A2 (enExample) |
| ZA (1) | ZA200906094B (enExample) |
Families Citing this family (123)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2620182A1 (en) * | 2005-08-22 | 2007-03-01 | Dennis A. Carson | Tlr agonists |
| US8846697B2 (en) | 2006-05-31 | 2014-09-30 | The Regents Of The University Of California | Purine analogs |
| EP2510946B1 (en) | 2007-02-07 | 2015-08-05 | The Regents of The University of California | Conjugates of synthetic tlr agonists and uses therefor |
| EP2211841A4 (en) * | 2007-10-15 | 2013-03-13 | Cooperative Res Ct For Asthma | METHOD FOR PROPHYLAXIS AND AGENTS FOR USE THEREIN |
| WO2009099650A2 (en) * | 2008-02-07 | 2009-08-13 | Carson Dennis A | Treatment of bladder diseases with a tlr7 activator |
| WO2010088924A1 (en) | 2009-02-06 | 2010-08-12 | Telormedix Sa | Pharmaceutical compositions comprising imidazoquinolin(amines) and derivatives thereof suitable for local administration |
| KR20110117705A (ko) * | 2009-02-11 | 2011-10-27 | 더 리전트 오브 더 유니버시티 오브 캘리포니아 | 톨-유사 수용체 조정제 및 질병의 치료 |
| WO2010138193A2 (en) * | 2009-05-27 | 2010-12-02 | Selecta Biosciences, Inc. | Targeted synthetic nanocarriers with ph sensitive release of immunomodulatory agents |
| BR112012009329A2 (pt) | 2009-10-22 | 2016-06-07 | Gilead Sciences Inc | derivados de purina ou deazapurina úteis para o tratamento de infecções virais (inter alia) |
| EP2563366A4 (en) * | 2010-04-30 | 2013-11-20 | Univ California | USE OF PHOSPHOLIPID CONJUGATES FROM SYNTHETIC TLR7 AGONISTS |
| EP2563404B1 (en) * | 2010-04-30 | 2016-09-21 | Urogen Pharma Ltd. | Phospholipid drug analogs |
| WO2011134669A1 (en) * | 2010-04-30 | 2011-11-03 | Telormedix Sa | Methods for inducing an immune response |
| US9050319B2 (en) | 2010-04-30 | 2015-06-09 | Telormedix, Sa | Phospholipid drug analogs |
| CN107029223A (zh) | 2010-05-26 | 2017-08-11 | 西莱克塔生物科技公司 | 合成纳米载体联合疫苗 |
| WO2012038058A1 (en) | 2010-09-21 | 2012-03-29 | Telormedix Sa | Treatment of conditions by toll-like receptor modulators |
| WO2012048113A2 (en) | 2010-10-07 | 2012-04-12 | The General Hospital Corporation | Biomarkers of cancer |
| EP2640190A4 (en) | 2010-11-05 | 2016-05-11 | Selecta Biosciences Inc | MODIFIED NICOTINIC COMPOUNDS AND ASSOCIATED METHODS |
| ES2691745T3 (es) | 2011-04-08 | 2018-11-28 | Janssen Sciences Ireland Uc | Derivados de pirimidina para el tratamiento de infecciones víricas |
| EP3153180A1 (en) * | 2011-06-03 | 2017-04-12 | 3M Innovative Properties Company | Heterobifunctional linkers with polyethylene glycol segments and immune response modifier conjugates made therefrom |
| BR112013031028A2 (pt) | 2011-06-03 | 2016-11-29 | 3M Innovative Properties Co | conectores heterobifuncionais com segmentos de polietileno glicol e conjugados de modificadores de resposta imunológica feitos a partir deles |
| JP2014521687A (ja) | 2011-07-29 | 2014-08-28 | セレクタ バイオサイエンシーズ インコーポレーテッド | 体液性および細胞傷害性ｔリンパ球（ｃｔｌ）免疫応答を生成する合成ナノキャリア |
| DK2776439T3 (en) | 2011-11-09 | 2018-10-22 | Janssen Sciences Ireland Uc | PURINE DERIVATIVES FOR TREATING VIRUS INFECTIONS |
| JP6375289B2 (ja) | 2012-04-05 | 2018-08-15 | マサチューセッツ インスティテュート オブ テクノロジー | 免疫刺激組成物およびその使用方法 |
| DK2872515T3 (en) | 2012-07-13 | 2016-09-19 | Janssen Sciences Ireland Uc | MACROCYCLIC PURINES FOR TREATING VIRUS INFECTIONS |
| CN112587671A (zh) * | 2012-07-18 | 2021-04-02 | 博笛生物科技有限公司 | 癌症的靶向免疫治疗 |
| WO2014052828A1 (en) | 2012-09-27 | 2014-04-03 | The Regents Of The University Of California | Compositions and methods for modulating tlr4 |
| CN111375056B (zh) * | 2012-10-10 | 2023-06-27 | 深圳大学 | 免疫受体调节剂偶联体及其制备方法和应用、制备其的偶联前体以及合成偶联前体的化合物 |
| MX386924B (es) | 2012-10-10 | 2025-03-19 | Janssen Sciences Ireland Uc | Derivados pirrolo[3,2-d]pirimidínicos para el tratamiento de infecciones víricas y otras enfermedades. |
| US9663474B2 (en) | 2012-11-16 | 2017-05-30 | Janssen Sciences Ireland Uc | Heterocyclic substituted 2-amino quinazoline derivatives for the treatment of viral infections |
| KR102300861B1 (ko) | 2013-02-21 | 2021-09-10 | 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 | 바이러스 감염의 치료를 위한 2-아미노피리미딘 유도체 |
| EP2958889B1 (en) | 2013-02-25 | 2017-03-22 | The Scripps Research Institute | Neoseptins: small molecule adjuvants |
| HK1220389A1 (zh) * | 2013-03-14 | 2017-05-05 | Wang Rongfu | 调控调节性t细胞功能的方法和组合物 |
| WO2014144365A1 (en) * | 2013-03-15 | 2014-09-18 | University Of Maryland, College Park | Nano-liposomal formulations and methods of use |
| WO2014154859A1 (en) | 2013-03-29 | 2014-10-02 | Janssen R&D Ireland | Macrocyclic deaza-purinones for the treatment of viral infections |
| UA117586C2 (uk) | 2013-05-24 | 2018-08-27 | ЯНССЕН САЙЄНСІЗ АЙРЛЕНД ЮСі | Похідні піридину для лікування вірусних інфекцій та інших захворювань |
| MX392130B (es) | 2013-06-27 | 2025-03-21 | Janssen Sciences Ireland Uc | Derivados de pirrolo[3,2-d]pirimidina para el tratamiento de infecciones víricas y otras enfermedades. |
| ES2836881T3 (es) | 2013-07-30 | 2021-06-28 | Janssen Sciences Ireland Unlimited Co | Derivados de tieno[3,2-d]pirimidinas para el tratamiento de infecciones virales |
| EP3033089A2 (en) * | 2013-08-16 | 2016-06-22 | The Regents of The University of California | Uses of phospholipid conjugates of synthetic tlr7 agonists |
| GB201321242D0 (en) | 2013-12-02 | 2014-01-15 | Immune Targeting Systems Its Ltd | Immunogenic compound |
| GB201321737D0 (en) * | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic Agents |
| EP3092256B1 (en) | 2014-01-10 | 2022-05-18 | Birdie Biopharmaceuticals Inc. | Compounds and compositions for immunotherapy |
| EP3161159B1 (en) | 2014-06-25 | 2020-08-05 | The General Hospital Corporation | Targeting human satellite ii (hsatii) |
| DK4001311T3 (da) | 2014-07-09 | 2026-02-02 | Birdie Biopharmaceuticals Inc | Anti-pd-l1/pd-1-kombinationer til behandling af tumorer |
| ES2944541T3 (es) | 2014-08-06 | 2023-06-22 | Scripps Research Inst | Adyuvantes de molécula pequeña independientes de TLR |
| CN112898308B (zh) * | 2014-08-15 | 2026-08-07 | 正大天晴药业集团股份有限公司 | 作为tlr7激动剂的吡咯并嘧啶化合物 |
| CN112546238A (zh) | 2014-09-01 | 2021-03-26 | 博笛生物科技有限公司 | 用于治疗肿瘤的抗-pd-l1结合物 |
| US10034901B2 (en) | 2015-01-22 | 2018-07-31 | University Of Massachusetts | Cancer immunotherapy |
| US10682314B2 (en) | 2015-05-26 | 2020-06-16 | Ohio State Innovation Foundation | Nanoparticle based vaccine strategy against swine influenza virus |
| CN108139375A (zh) | 2015-06-26 | 2018-06-08 | 贝斯以色列女执事医疗中心股份有限公司 | 靶向髓样衍生的抑制细胞中的四跨膜蛋白33(tspan33)的癌症疗法 |
| CA2998995A1 (en) * | 2015-09-29 | 2017-04-06 | Astrazeneca Aktiebolag | Adenine conjugate compounds and their use as vaccine adjuvants |
| CN105311032B (zh) * | 2015-11-09 | 2018-09-25 | 深圳大学 | Tlr7激动剂与酪氨酸激酶抑制剂联用在制备抗肿瘤药物中的应用 |
| CN105315281B (zh) * | 2015-11-16 | 2017-04-19 | 深圳大学 | 化合物i和化合物ii及其制备方法和应用 |
| CN106943598A (zh) | 2016-01-07 | 2017-07-14 | 博笛生物科技（北京）有限公司 | 用于治疗肿瘤的抗-her2组合 |
| CN106943597A (zh) | 2016-01-07 | 2017-07-14 | 博笛生物科技（北京）有限公司 | 用于治疗肿瘤的抗-egfr组合 |
| CN106943596A (zh) | 2016-01-07 | 2017-07-14 | 博笛生物科技（北京）有限公司 | 用于治疗肿瘤的抗-cd20组合 |
| KR102483033B1 (ko) * | 2016-05-16 | 2022-12-30 | 액세스 투 어드밴스드 헬스 인스티튜트 | 페길화된 리포솜 및 이의 용도 |
| US11697851B2 (en) | 2016-05-24 | 2023-07-11 | The Regents Of The University Of California | Early ovarian cancer detection diagnostic test based on mRNA isoforms |
| MA45539A (fr) | 2016-07-01 | 2019-05-08 | Janssen Sciences Ireland Unlimited Co | Dihydropyranopyrimidines pour le traitement d'infections virales |
| WO2018013924A1 (en) | 2016-07-15 | 2018-01-18 | Massachusetts Institute Of Technology | Synthetic nanoparticles for delivery of immunomodulatory compounds |
| SG10202010317VA (en) | 2016-09-29 | 2020-11-27 | Janssen Sciences Ireland Unlimited Co | Pyrimidine prodrugs for the treatment of viral infections and further diseases |
| WO2018077385A1 (en) * | 2016-10-25 | 2018-05-03 | Biontech Rna Pharmaceuticals Gmbh | Dose determination for immunotherapeutic agents |
| WO2018081817A2 (en) | 2016-10-31 | 2018-05-03 | University Of Massachusetts | Targeting microrna-101-3p in cancer therapy |
| WO2018089688A1 (en) | 2016-11-09 | 2018-05-17 | Jinjun Shi | Restoration of tumor suppression using mrna-based delivery system |
| CA3045944A1 (en) | 2016-12-07 | 2018-06-14 | Progenity, Inc. | Gastrointestinal tract detection methods, devices and systems |
| WO2018112223A1 (en) | 2016-12-14 | 2018-06-21 | Progenity Inc. | Treatment of a disease of the gastrointestinal tract with a tlr modulator |
| JP7161760B2 (ja) * | 2017-02-03 | 2022-10-27 | 国立大学法人東北大学 | 複素環化合物 |
| CN108794467A (zh) | 2017-04-27 | 2018-11-13 | 博笛生物科技有限公司 | 2-氨基-喹啉衍生物 |
| FI3641771T3 (fi) | 2017-06-23 | 2026-08-11 | Birdie Biopharmaceuticals Inc | Farmaseuttisia koostumuksia |
| US20200163880A1 (en) | 2017-07-13 | 2020-05-28 | Danmarks Tekniske Universitet | Cationic liposomes |
| US10494370B2 (en) | 2017-08-16 | 2019-12-03 | Bristol-Myers Squibb Company | Toll-like receptor 7 (TLR7) agonists having a pyridine or pyrazine moiety, conjugates thereof, and methods and uses therefor |
| US10472361B2 (en) | 2017-08-16 | 2019-11-12 | Bristol-Myers Squibb Company | Toll-like receptor 7 (TLR7) agonists having a benzotriazole moiety, conjugates thereof, and methods and uses therefor |
| US10487084B2 (en) | 2017-08-16 | 2019-11-26 | Bristol-Myers Squibb Company | Toll-like receptor 7 (TLR7) agonists having a heterobiaryl moiety, conjugates thereof, and methods and uses therefor |
| US10457681B2 (en) | 2017-08-16 | 2019-10-29 | Bristol_Myers Squibb Company | Toll-like receptor 7 (TLR7) agonists having a tricyclic moiety, conjugates thereof, and methods and uses therefor |
| US10508115B2 (en) | 2017-08-16 | 2019-12-17 | Bristol-Myers Squibb Company | Toll-like receptor 7 (TLR7) agonists having heteroatom-linked aromatic moieties, conjugates thereof, and methods and uses therefor |
| CA3089562A1 (en) | 2018-01-30 | 2019-08-08 | University Of Massachusetts | Methods of treating a wound using epigenetic regulation |
| EP4317972A3 (en) | 2018-02-06 | 2024-03-13 | The General Hospital Corporation | Repeat rna as biomarkers of tumor immune response |
| TW202415645A (zh) | 2018-03-01 | 2024-04-16 | 愛爾蘭商健生科學愛爾蘭無限公司 | ２，４－二胺基喹唑啉衍生物及其醫學用途 |
| CN110317202B (zh) * | 2018-03-30 | 2021-12-24 | 江苏恒瑞医药股份有限公司 | 氰基吡咯并杂芳基类衍生物、其制备方法及其在医药上的应用 |
| CN115192726A (zh) | 2018-04-03 | 2022-10-18 | 深圳大学 | 免疫激动剂靶向化合物的合成及其应用 |
| WO2019197598A1 (en) * | 2018-04-13 | 2019-10-17 | Glaxosmithkline Biologicals Sa | Tlr7 and / or tlr8 agonists |
| WO2019196918A1 (zh) * | 2018-04-13 | 2019-10-17 | 罗欣药业(上海)有限公司 | 五元杂环并嘧啶类化合物、药物组合物及用途 |
| WO2019209811A1 (en) | 2018-04-24 | 2019-10-31 | Bristol-Myers Squibb Company | Macrocyclic toll-like receptor 7 (tlr7) agonists |
| US11554120B2 (en) | 2018-08-03 | 2023-01-17 | Bristol-Myers Squibb Company | 1H-pyrazolo[4,3-d]pyrimidine compounds as toll-like receptor 7 (TLR7) agonists and methods and uses therefor |
| WO2020041720A1 (en) | 2018-08-24 | 2020-02-27 | Codiak Biosciences, Inc. | Extracellular vesicles targeting dendritic cells and uses thereof |
| AU2019400340A1 (en) * | 2018-12-17 | 2021-05-20 | Eisai R&D Management Co., Ltd. | Formulation comprising liposomes |
| JP2022519275A (ja) | 2019-02-04 | 2022-03-22 | コディアック バイオサイエンシーズ， インコーポレイテッド | エクソソーム操作のための膜タンパク質足場 |
| AU2020236254B2 (en) * | 2019-03-14 | 2026-07-09 | The Regents Of The University Of California | TLR4-TLR7 ligand formulations as vaccine adjuvants |
| JP2022525781A (ja) | 2019-03-20 | 2022-05-19 | マサチューセッツ インスティテュート オブ テクノロジー | 免疫細胞療法における両親媒性物質の使用およびそのための組成物 |
| WO2020191361A2 (en) | 2019-03-21 | 2020-09-24 | Codiak Biosciences, Inc. | Extracellular vesicles for vaccine delivery |
| EP3941607A1 (en) | 2019-03-21 | 2022-01-26 | Codiak BioSciences, Inc. | Process for preparing extracellular vesicles |
| KR20210141554A (ko) | 2019-03-21 | 2021-11-23 | 코디악 바이오사이언시즈, 인크. | 세포외 소포 접합체 및 이의 용도 |
| US20220251200A1 (en) | 2019-07-03 | 2022-08-11 | Codiak Biosciences, Inc. | Extracellular vesicles targeting t cells and uses thereof |
| WO2021053163A1 (en) | 2019-09-19 | 2021-03-25 | Danmarks Tekniske Universitet | Immune stimulating micelle composition |
| CN114727947A (zh) | 2019-09-25 | 2022-07-08 | 科迪亚克生物科学公司 | 细胞外囊泡组合物 |
| US11744874B2 (en) | 2019-12-20 | 2023-09-05 | Nammi Therapeutics, Inc. | Formulated and/or co-formulated liposome compositions containing toll-like receptor (“TLR”) agonist prodrugs useful in the treatment of cancer and methods thereof |
| JP2023512206A (ja) | 2020-01-27 | 2023-03-24 | ブリストル－マイヤーズ スクイブ カンパニー | トール様受容体７（ＴＬＲ７）アゴニストとしての１Ｈ－ピラゾロ［４，３－ｄ］ピリミジン化合物 |
| US20230127326A1 (en) | 2020-01-27 | 2023-04-27 | Bristol-Myers Squibb Company | C3-SUBSTITUTED 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS |
| KR20220132594A (ko) | 2020-01-27 | 2022-09-30 | 브리스톨-마이어스 스큅 컴퍼니 | 톨-유사 수용체 7 (TLR7) 효능제로서의 1H-피라졸로[4,3-d]피리미딘 화합물 |
| CN115210235A (zh) | 2020-01-27 | 2022-10-18 | 百时美施贵宝公司 | 作为Toll样受体7(TLR7)激动剂的1H-吡唑并[4,3-d]嘧啶化合物 |
| JP7684316B2 (ja) | 2020-01-27 | 2025-05-27 | ブリストル－マイヤーズ スクイブ カンパニー | トール様受容体７（ＴＬＲ７）アゴニストとしての１Ｈ－ピラゾロ［４，３－ｄ］ピリミジン化合物 |
| JP7712941B2 (ja) | 2020-01-27 | 2025-07-24 | ブリストル－マイヤーズ スクイブ カンパニー | トール様受容体７（ＴＬＲ７）アゴニストとしての１Ｈ－ピラゾロ［４，３－ｄ］ピリミジン化合物 |
| WO2021154662A1 (en) | 2020-01-27 | 2021-08-05 | Bristol-Myers Squibb Company | 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS |
| CN115151547A (zh) | 2020-01-27 | 2022-10-04 | 百时美施贵宝公司 | 作为Toll样受体7(TLR7)激动剂的1H-吡唑并[4,3-d]嘧啶化合物 |
| CN115279765B (zh) | 2020-01-27 | 2024-11-12 | 百时美施贵宝公司 | 作为Toll样受体7(TLR7)激动剂的1H-吡唑并[4,3-d]嘧啶化合物 |
| US11179473B2 (en) | 2020-02-21 | 2021-11-23 | Silverback Therapeutics, Inc. | Nectin-4 antibody conjugates and uses thereof |
| WO2021174024A1 (en) | 2020-02-28 | 2021-09-02 | First Wave Bio, Inc. | Methods of treating iatrogenic autoimmune colitis |
| WO2021184017A1 (en) | 2020-03-13 | 2021-09-16 | Codiak Biosciences, Inc. | Extracellular vesicles for treating neurological disorders |
| JP2023518414A (ja) | 2020-03-20 | 2023-05-01 | コディアック バイオサイエンシーズ， インコーポレイテッド | 治療のための細胞外小胞 |
| EP4149550A4 (en) * | 2020-05-15 | 2024-07-03 | The Board of Trustees of the Leland Stanford Junior University | TOLL-LIKE RECEPTOR (TLR) AGONIST NANOPARTICLES AND USES THEREOF |
| WO2021237100A1 (en) | 2020-05-21 | 2021-11-25 | Codiak Biosciences, Inc. | Methods of targeting extracellular vesicles to lung |
| US20230220068A1 (en) | 2020-06-05 | 2023-07-13 | Codiak Biosciences, Inc. | Anti-transferrin extracellular vesicles |
| CN111892648B (zh) * | 2020-06-08 | 2022-08-26 | 中国科学院上海药物研究所 | 偶联tlr7激动剂的新型冠状病毒多肽疫苗及其应用 |
| KR20230047361A (ko) | 2020-07-01 | 2023-04-07 | 아르스 파마슈티컬스 인크. | 항-asgr1 항체 접합체 및 이의 용도 |
| EP4175640A1 (en) | 2020-07-02 | 2023-05-10 | VIIV Healthcare Company | Method of achieving hiv viral remission using long-acting antiretroviral agents |
| WO2022066898A2 (en) | 2020-09-23 | 2022-03-31 | Codiak Biosciences, Inc. | Methods of producing extracellular vesicles |
| WO2022066883A1 (en) | 2020-09-23 | 2022-03-31 | Codiak Biosciences, Inc. | Extracellular vesicles comprising kras antigens and uses thereof |
| WO2022066928A2 (en) | 2020-09-23 | 2022-03-31 | Codiak Biosciences, Inc. | Process for preparing extracellular vesicles |
| EP4232094A1 (en) * | 2020-10-21 | 2023-08-30 | Univerza V Ljubljani | Conjugated tlr7 and nod2 agonists |
| US20240197759A1 (en) | 2021-03-25 | 2024-06-20 | Danmarks Tekniske Universitet | Immune stimulating nanoparticle composition |
| WO2022246764A1 (zh) * | 2021-05-27 | 2022-12-01 | 中科蓝华(广州)生物医药技术有限公司 | 一种分析cd303+树突状细胞亚群表型和功能的方法及试剂盒 |
| AU2022380909A1 (en) * | 2021-11-03 | 2024-06-06 | Adcentrx Therapeutics Inc. | Drug conjugates and methods of preparing and using the same |
| CN116162088B (zh) * | 2022-12-14 | 2025-03-11 | 江苏省农业科学院 | 一种Toll样受体7激动剂纳米颗粒及其制备方法与应用 |
| WO2025043547A1 (zh) | 2023-08-30 | 2025-03-06 | 杭州高田生物医药有限公司 | T细胞导向免疫脂质体及其用途 |
Family Cites Families (89)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4559157A (en) | 1983-04-21 | 1985-12-17 | Creative Products Resource Associates, Ltd. | Cosmetic applicator useful for skin moisturizing |
| LU84979A1 (fr) | 1983-08-30 | 1985-04-24 | Oreal | Composition cosmetique ou pharmaceutique sous forme aqueuse ou anhydre dont la phase grasse contient un polyether oligomere et polyethers oligomeres nouveaux |
| IL73534A (en) | 1983-11-18 | 1990-12-23 | Riker Laboratories Inc | 1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds |
| CA1271477A (en) | 1983-11-18 | 1990-07-10 | John F. Gerster | 1h-imidazo[4,5-c]quinolin-4-amines |
| US4820508A (en) | 1987-06-23 | 1989-04-11 | Neutrogena Corporation | Skin protective composition |
| US4992478A (en) | 1988-04-04 | 1991-02-12 | Warner-Lambert Company | Antiinflammatory skin moisturizing composition and method of preparing same |
| US4938949A (en) | 1988-09-12 | 1990-07-03 | University Of New York | Treatment of damaged bone marrow and dosage units therefor |
| US5238944A (en) | 1988-12-15 | 1993-08-24 | Riker Laboratories, Inc. | Topical formulations and transdermal delivery systems containing 1-isobutyl-1H-imidazo[4,5-c]quinolin-4-amine |
| US5736553A (en) | 1988-12-15 | 1998-04-07 | Riker Laboratories, Inc. | Topical formulations and transdermal delivery systems containing 1-isobutyl-1H-imidazo 4,5-C!quinolin-4-amine |
| US4929624A (en) | 1989-03-23 | 1990-05-29 | Minnesota Mining And Manufacturing Company | Olefinic 1H-imidazo(4,5-c)quinolin-4-amines |
| US5037986A (en) | 1989-03-23 | 1991-08-06 | Minnesota Mining And Manufacturing Company | Olefinic 1H-imidazo[4,5-c]quinolin-4-amines |
| NZ232740A (en) | 1989-04-20 | 1992-06-25 | Riker Laboratories Inc | Solution for parenteral administration comprising a 1h-imidazo(4,5-c) quinolin-4-amine derivative, an acid and a tonicity adjuster |
| DK0553202T3 (da) | 1990-10-05 | 1995-07-03 | Minnesota Mining & Mfg | Fremgangsmåde til fremstilling af imidazo(4,5-c)quinolin-4-aminer |
| US5175296A (en) | 1991-03-01 | 1992-12-29 | Minnesota Mining And Manufacturing Company | Imidazo[4,5-c]quinolin-4-amines and processes for their preparation |
| IL105325A (en) | 1992-04-16 | 1996-11-14 | Minnesota Mining & Mfg | Immunogen/vaccine adjuvant composition |
| US5395937A (en) | 1993-01-29 | 1995-03-07 | Minnesota Mining And Manufacturing Company | Process for preparing quinoline amines |
| US5352784A (en) | 1993-07-15 | 1994-10-04 | Minnesota Mining And Manufacturing Company | Fused cycloalkylimidazopyridines |
| US5648516A (en) | 1994-07-20 | 1997-07-15 | Minnesota Mining And Manufacturing Company | Fused cycloalkylimidazopyridines |
| US5525606A (en) | 1994-08-01 | 1996-06-11 | The United States Of America As Represented By The Department Of Health And Human Services | Substituted 06-benzylguanines and 6(4)-benzyloxypyrimidines |
| DE19505168A1 (de) | 1995-02-16 | 1996-08-22 | Boehringer Mannheim Gmbh | Spezifische Lipidkonjugate von Nucleosid-Diphosphonaten und deren Verwendung als Arzneimittel |
| US5624677A (en) | 1995-06-13 | 1997-04-29 | Pentech Pharmaceuticals, Inc. | Controlled release of drugs delivered by sublingual or buccal administration |
| US5693811A (en) | 1996-06-21 | 1997-12-02 | Minnesota Mining And Manufacturing Company | Process for preparing tetrahdroimidazoquinolinamines |
| US5741908A (en) | 1996-06-21 | 1998-04-21 | Minnesota Mining And Manufacturing Company | Process for reparing imidazoquinolinamines |
| DE19637209B4 (de) | 1996-09-12 | 2006-12-14 | Siemens Ag | Verfahren zum Steuern des Antriebsstrangs eines Kraftfahrzeugs und integrierte Antriebsstrangsteuerung |
| DE69735292T2 (de) | 1996-10-25 | 2006-10-19 | Gilead Sciences, Inc., Foster City | Gefaesszellen wachstumsfaktor (vegf) nukleinsäureligand-komplexe |
| JP4391592B2 (ja) | 1996-10-25 | 2009-12-24 | スリーエム カンパニー | Ｔｈ２介在性および関連疾患治療のための免疫応答修飾化合物 |
| JPH10298181A (ja) | 1997-04-25 | 1998-11-10 | Sumitomo Pharmaceut Co Ltd | タイプ２ヘルパーｔ細胞選択的免疫応答抑制剤 |
| DE69824632T2 (de) | 1997-11-12 | 2005-06-09 | Mitsubishi Chemical Corp. | Purinderivate und medikamente, welche dieselben als aktiven bestandteil enthalten |
| JP4375901B2 (ja) | 1997-11-28 | 2009-12-02 | 大日本住友製薬株式会社 | 新規な複素環化合物 |
| JP4189048B2 (ja) | 1997-12-26 | 2008-12-03 | 大日本住友製薬株式会社 | 複素環化合物 |
| US7001609B1 (en) | 1998-10-02 | 2006-02-21 | Regents Of The University Of Minnesota | Mucosal originated drug delivery systems and animal applications |
| US20020058674A1 (en) | 1999-01-08 | 2002-05-16 | Hedenstrom John C. | Systems and methods for treating a mucosal surface |
| US6486168B1 (en) | 1999-01-08 | 2002-11-26 | 3M Innovative Properties Company | Formulations and methods for treatment of mucosal associated conditions with an immune response modifier |
| PL349773A1 (en) | 1999-01-08 | 2002-09-09 | 3M Innovative Properties Co | Formulations comprising imiquimod or other immune response modifiers for treating mucosal conditions |
| CZ27399A3 (cs) | 1999-01-26 | 2000-08-16 | Ústav Experimentální Botaniky Av Čr | Substituované dusíkaté heterocyklické deriváty, způsob jejich přípravy, tyto deriváty pro použití jako léčiva, farmaceutická kompozice a kombinovaný farmaceutický přípravek tyto deriváty obsahující a použití těchto derivátů pro výrobu léčiv |
| WO2001044260A2 (en) | 1999-12-17 | 2001-06-21 | Ariad Pharmaceuticals, Inc. | Novel purines |
| ATE345349T1 (de) | 1999-12-17 | 2006-12-15 | Ariad Pharma Inc | Purinderivate |
| US20030187261A1 (en) | 2000-01-07 | 2003-10-02 | Libor Havlicek | Purine derivatives, process for their preparation and use thereof |
| US6733764B2 (en) | 2000-06-14 | 2004-05-11 | Alain Martin | Immunostimulator anti-cancer compounds and methods for their use in the treatment of cancer |
| US20040023211A1 (en) | 2000-09-15 | 2004-02-05 | Kees Groen | System and method for optimizing drug theraphy for the treatment of diseases |
| GB0023008D0 (en) | 2000-09-20 | 2000-11-01 | Glaxo Group Ltd | Improvements in vaccination |
| AU2002211602A1 (en) | 2000-10-11 | 2002-04-22 | Johns Hopkins University | Polymer controlled delivery of a therapeutic agent |
| US20020127224A1 (en) | 2001-03-02 | 2002-09-12 | James Chen | Use of photoluminescent nanoparticles for photodynamic therapy |
| WO2002081443A1 (en) | 2001-04-09 | 2002-10-17 | Chiron Corporation | Novel guanidino compounds |
| JP4331944B2 (ja) | 2001-04-17 | 2009-09-16 | 大日本住友製薬株式会社 | 新規アデニン誘導体 |
| EP3231445A1 (en) | 2001-05-18 | 2017-10-18 | Sirna Therapeutics, Inc. | Conjugates and compositions for cellular delivery |
| ATE307132T1 (de) | 2001-06-29 | 2005-11-15 | Cv Therapeutics Inc | Purin derivate als a2b adenosin rezeptor antagonisten |
| EP1440072A4 (en) | 2001-10-30 | 2005-02-02 | Conforma Therapeutic Corp | PURINE ANALOGS HAVING HSP90 INHIBITORY ACTIVITY |
| GB0206461D0 (en) | 2002-03-19 | 2002-05-01 | Glaxo Group Ltd | Improvements in vaccination |
| WO2004032829A2 (en) | 2002-08-15 | 2004-04-22 | 3M Innovative Properties Company | Immunostimulatory compositions and methods of stimulating an immune response |
| CA2497765A1 (en) | 2002-09-27 | 2004-04-08 | Sumitomo Pharmaceuticals Co., Ltd. | 8-hydroxy substituted adenine compounds and uses thereof |
| JP2004137157A (ja) | 2002-10-16 | 2004-05-13 | Sumitomo Pharmaceut Co Ltd | 新規アデニン誘導体を有効成分として含有する医薬 |
| EP1608384A2 (en) | 2003-01-28 | 2005-12-28 | Shanghai Sunway Biotech Co Ltd | Therapy for primary and metastatic cancers |
| US20040265351A1 (en) | 2003-04-10 | 2004-12-30 | Miller Richard L. | Methods and compositions for enhancing immune response |
| WO2005016235A2 (en) | 2003-04-14 | 2005-02-24 | The Regents Of The University Of California | Combined use of impdh inhibitors with toll-like receptor agonists |
| US20050059613A1 (en) | 2003-07-08 | 2005-03-17 | Bahram Memarzadeh | Compositions and methods for the enhanced uptake of therapeutic agents through the bladder epithelium |
| WO2005020892A2 (en) | 2003-08-08 | 2005-03-10 | Mitochroma Research, Inc. | Pharmaceutical compositions and methods for metabolic modulation |
| EP1667694B1 (en) | 2003-09-05 | 2010-04-28 | Anadys Pharmaceuticals, Inc. | Tlr7 ligands for the treatment of hepatitis c |
| JP2005089334A (ja) | 2003-09-12 | 2005-04-07 | Sumitomo Pharmaceut Co Ltd | ８−ヒドロキシアデニン化合物 |
| NZ546611A (en) | 2003-09-18 | 2010-02-26 | Conforma Therapeutics Corp | Novel heterocyclic compounds as HSP90-inhibitors |
| FR2863890B1 (fr) * | 2003-12-19 | 2006-03-24 | Aventis Pasteur | Composition immunostimulante |
| JP2007526322A (ja) | 2004-03-02 | 2007-09-13 | マサチューセッツ インスティテュート オブ テクノロジー | ナノセル薬物送達系 |
| BRPI0509258A8 (pt) | 2004-03-26 | 2019-01-22 | Astrazeneca Ab | composto de 8-oxoadenina 9-substituída |
| WO2005092892A1 (ja) * | 2004-03-26 | 2005-10-06 | Dainippon Sumitomo Pharma Co., Ltd. | ８−オキソアデニン化合物 |
| WO2006054129A1 (en) | 2004-11-19 | 2006-05-26 | Institut Gustave Roussy | Improved treatment of cancer by double-stranded rna |
| US8105632B2 (en) | 2004-12-07 | 2012-01-31 | University Of Miami | Cell-derived microparticles as hemostatic agents for control of hemorrhage and treatment of bleeding disorders |
| BRPI0609399A2 (pt) | 2005-03-21 | 2010-03-30 | Ferrer Int | método para produzir compostos da 1h-imidazo[4,5-c]quinolin-4-amina 1-substituìda e intermediários dos mesmos |
| US20070292418A1 (en) | 2005-04-26 | 2007-12-20 | Eisai Co., Ltd. | Compositions and methods for immunotherapy |
| CA2620182A1 (en) | 2005-08-22 | 2007-03-01 | Dennis A. Carson | Tlr agonists |
| EP1939202A4 (en) | 2005-09-22 | 2010-06-16 | Dainippon Sumitomo Pharma Co | NEW ADENINE CONNECTION |
| WO2007034917A1 (ja) * | 2005-09-22 | 2007-03-29 | Dainippon Sumitomo Pharma Co., Ltd. | 新規なアデニン化合物 |
| WO2007038720A2 (en) | 2005-09-27 | 2007-04-05 | Coley Pharmaceutical Gmbh | Modulation of tlr-mediated immune responses using adaptor oligonucleotides |
| US20070100146A1 (en) | 2005-11-03 | 2007-05-03 | Trevor Dzwiniel | Process for the preparation of imidazo[4,5-c]-quinolin-4-amines |
| US8846697B2 (en) | 2006-05-31 | 2014-09-30 | The Regents Of The University Of California | Purine analogs |
| US8338593B2 (en) | 2006-07-07 | 2012-12-25 | Gilead Sciences, Inc. | Modulators of toll-like receptor 7 |
| TW200831104A (en) | 2006-10-04 | 2008-08-01 | Pharmacopeia Inc | 6-substituted 2-(benzimidazolyl)purine and purinone derivatives for immunosuppression |
| US7902187B2 (en) | 2006-10-04 | 2011-03-08 | Wyeth Llc | 6-substituted 2-(benzimidazolyl)purine and purinone derivatives for immunosuppression |
| EP2510946B1 (en) | 2007-02-07 | 2015-08-05 | The Regents of The University of California | Conjugates of synthetic tlr agonists and uses therefor |
| EP2170888B1 (en) | 2007-06-29 | 2015-04-22 | Gilead Sciences, Inc. | Purine derivatives and their use as modulators of toll-like receptor 7 |
| JP2011500716A (ja) | 2007-10-16 | 2011-01-06 | ギリアード・パロ・アルト・インコーポレイテッド | Ａ３アデノシン受容体アンタゴニスト |
| WO2009099650A2 (en) | 2008-02-07 | 2009-08-13 | Carson Dennis A | Treatment of bladder diseases with a tlr7 activator |
| WO2010088924A1 (en) | 2009-02-06 | 2010-08-12 | Telormedix Sa | Pharmaceutical compositions comprising imidazoquinolin(amines) and derivatives thereof suitable for local administration |
| KR20110117705A (ko) | 2009-02-11 | 2011-10-27 | 더 리전트 오브 더 유니버시티 오브 캘리포니아 | 톨-유사 수용체 조정제 및 질병의 치료 |
| BR112012009329A2 (pt) | 2009-10-22 | 2016-06-07 | Gilead Sciences Inc | derivados de purina ou deazapurina úteis para o tratamento de infecções virais (inter alia) |
| EP2563404B1 (en) | 2010-04-30 | 2016-09-21 | Urogen Pharma Ltd. | Phospholipid drug analogs |
| WO2011134669A1 (en) | 2010-04-30 | 2011-11-03 | Telormedix Sa | Methods for inducing an immune response |
| EP2563366A4 (en) | 2010-04-30 | 2013-11-20 | Univ California | USE OF PHOSPHOLIPID CONJUGATES FROM SYNTHETIC TLR7 AGONISTS |
| JP2013538217A (ja) | 2010-09-01 | 2013-10-10 | ノバルティス アーゲー | 不溶性金属塩への免疫増強物質の吸着 |
| WO2012038058A1 (en) | 2010-09-21 | 2012-03-29 | Telormedix Sa | Treatment of conditions by toll-like receptor modulators |
-
2008
- 2008-02-07 EP EP12004181.9A patent/EP2510946B1/en active Active
- 2008-02-07 SI SI200831521T patent/SI2510946T1/sl unknown
- 2008-02-07 US US12/027,960 patent/US8357374B2/en active Active
- 2008-02-07 WO PCT/US2008/001631 patent/WO2008115319A2/en not_active Ceased
- 2008-02-07 ES ES08799591.6T patent/ES2456964T3/es active Active
- 2008-02-07 ES ES12004181.9T patent/ES2552471T3/es active Active
- 2008-02-07 CA CA002677733A patent/CA2677733A1/en not_active Abandoned
- 2008-02-07 KR KR1020097018499A patent/KR20090109121A/ko not_active Ceased
- 2008-02-07 PT PT120041819T patent/PT2510946E/pt unknown
- 2008-02-07 AU AU2008227128A patent/AU2008227128B2/en active Active
- 2008-02-07 DK DK12004181.9T patent/DK2510946T3/en active
- 2008-02-07 EA EA200901078A patent/EA019151B1/ru unknown
- 2008-02-07 HU HUE12004181A patent/HUE025555T2/en unknown
- 2008-02-07 PL PL12004181T patent/PL2510946T3/pl unknown
- 2008-02-07 EP EP08799591.6A patent/EP2125007B9/en active Active
- 2008-02-07 CN CN2008800115258A patent/CN101790380B/zh active Active
- 2008-02-07 JP JP2009549102A patent/JP5425642B2/ja not_active Expired - Fee Related
- 2008-02-07 PL PL08799591T patent/PL2125007T3/pl unknown
-
2009
- 2009-08-05 IL IL200240A patent/IL200240A/en active IP Right Grant
- 2009-09-02 ZA ZA2009/06094A patent/ZA200906094B/en unknown
-
2013
- 2013-01-08 US US13/736,545 patent/US8790655B2/en active Active
- 2013-03-22 JP JP2013059721A patent/JP2013127004A/ja not_active Withdrawn
-
2014
- 2014-06-19 US US14/309,245 patent/US9050376B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL200240A0 (en) | Conjugates of synthetic tlr agonists and uses therefor | |
| EP2079305A4 (en) | SYNTHETIC AGONISTS OF TLR9 | |
| ZA201104495B (en) | Conjugates of neurotensin or neurotensin analogs and uses thereof | |
| ZA201103044B (en) | Conjugates of glp-1 agonists and uses thereof | |
| SG10201801503XA (en) | e-POLYLYSINE CONJUGATES AND USE THEREOF | |
| HUE059436T2 (hu) | PSMA-kötõ szerek és alkalmazásaik | |
| ZA201101896B (en) | Frizzled-binding agents and uses thereof | |
| EP2173912A4 (en) | NEW SYNTHETIC AGONISTS OF TLR9 | |
| IL218678A0 (en) | Protein kinase conjugates and inhibitors | |
| IL209309A0 (en) | Anti-fn14 antibodies and uses thereof | |
| ZA201001206B (en) | Saccharide-containing protein conjugates and uses thereof | |
| IL216731A (en) | And antibodies against p95 – her2 and their uses | |
| PT2268401T (pt) | Ensaios | |
| IL212199A0 (en) | Hpma- docetaxel or gemcitabine conjugates and uses therefore | |
| IL206146A0 (en) | Dibenzoazepine and dibenzooxazepine trpa1 agonists | |
| IL200845A0 (en) | Oligomer-opoid agonist conjugates | |
| IL216626A0 (en) | Albumin-amyloid peptide conjugates and uses thereof | |
| LT2300033T (lt) | Kolageno peptido konjugatai ir jų panaudojimas | |
| GB0812277D0 (en) | Antibody and uses thereof | |
| GB0800698D0 (en) | F2 polypeptides and usesthereof | |
| IL211545A0 (en) | Leucojum bulb extracts and use thereof |